MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Strona główna・Stock List・Gossamer Bio Inc

Gossamer Bio Inc

Closed

SectorHealthcare

2.54 -4.51

Buy Sell

Overview

Share price change

24h

Current

Min

2.4699999999999998

Max

2.6

Key metrics
By Trading Economics
Income	-9.9M -48M
Sales	1.8M 13M
Profit margin	-362.728
Employees	144
EBITDA	-10M -45M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+389.29% upside

Dividends
By Dow Jones
Next Earnings	11 mar 2026

Market Stats
By TradingEconomics
Market Cap	36M 583M
Previous open	7.05
Previous close	2.54

News Sentiment

By Acuity

50%

151 / 361 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

1.06 / 1.23 Support & Resistance

Gossamer Bio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sty 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 sty 2026, 00:00 UTC

Earnings

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 sty 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 sty 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 sty 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 sty 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 sty 2026, 22:56 UTC

Acquisitions, Mergers, Takeovers

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 sty 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 sty 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14 sty 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 sty 2026, 22:09 UTC

Earnings

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 sty 2026, 22:08 UTC

Earnings

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 sty 2026, 22:08 UTC

Earnings

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 sty 2026, 21:53 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 sty 2026, 21:53 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 sty 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Announces Positive Profit Alert for 2025

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Citigroup Acting as Financial Advisor to WuXi XDC

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 sty 2026, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

14 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 sty 2026, 21:49 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 sty 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 sty 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Makes Cash Offer for BioDlink International

14 sty 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 sty 2026, 20:30 UTC

Market Talk

Earnings

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 sty 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 sty 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 sty 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 sty 2026, 19:06 UTC

Market Talk

Earnings

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Peer Comparison

Price change

Gossamer Bio Inc Forecast

Price Target

By TipRanks

389.29% upside

12 Months Forecast

Average 12.33 USD 389.29%

High 15 USD

Low 10 USD

Based on 4 Wall Street analysts offering 12 month price targets forGossamer Bio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Gossamer Bio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.06 / 1.23Support & Resistance

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

151 / 361 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.